In Section C, members will acquire ABBV-744 and oral navitoclax. In Phase D, participants will receive ABBV-744 and ruxolitinib. Contributors will acquire treatment right up until disease progression or the contributors are unable to tolerate the study drugs. There might be bigger treatment stress for contributors On this trial compared https://mayav009grc2.answerblogs.com/profile